Visipaque™ (Iodixanol) Injection
Visipaque™ (iodixanol) injection - the only contrast media for intravascular use that is iso-osmolar to blood and isotonic at all concentrations in the US
Visipaque: Prepared for high risk patients
More than 1 in 7 adults in the US are estimated to have CKD, and most don't know it.³ 34.2 million Americans - just over 1 in 10 - have diabetes.⁴ By 2060, 1 in 4 people in the US will be aged 65+, with the number over 85 years expected to nearly triple.⁵
Appropriate selection of contrast media for necessary diagnostic or interventional procedure imaging in high risk patients should be considered to help mitigate the risk of adverse events.⁶ Visipaque, an iodinated iso-osmolar, isotonic contrast agent indicated for multiple intra-arterial and intravenous procedures, was prepared with this in mind.
FEATURES
Your choice of iodinated contrast media could help mitigate adverse events
Interventional, structural, or endovascular procedures (e.g., TAVI, CTO, PCI) may need to use higher volumes of iodinated CM. Reducing the frequency of adverse reactions has therefore been a driving force in the development of these diagnostic agents since their initial introduction
SAFETY
High risk patient populations are ever growing^8,9
Visipaque is a third-generation agent with a unique molecular structure developed to further improve the safety profile of iodinated contrast agents.^8,10 It is iso-osmolar to blood with the aim of counteracting major fluid shifts across membranes and limiting discomfort.^10,11 It is also formulated with balanced electrolytes to help minimize effects on cardiac contractile force/fibrillatory propensity.^10,11 While 'low' osmolar agents form the mainstay in the general population of patients undergoing endovascular diagnostic or interventional procedures, Visipaque may be preferred for more complex procedures in patients considered at high risk for cardiovascular or renal insult.^1,8
VALUE
Can help reduce cost by helping to reduce risk
When compared to total interventional procedure cost, contrast media is inexpensive but CA-AKI and contrast media-related adverse events may increase the use of health care resources and cost of care.¹⁵ Given the growth of vulnerable patient populations, practices that reduce CA-AKI incidence and its associated costs are important to identify.